U3-1287 + Erlotinib + Placebo
Phase 1/2Completed 3 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC (Advanced Non-small Cell Lung Cancer)
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Trial Timeline
Sep 1, 2010 → Nov 23, 2013
NCT ID
NCT01211483About U3-1287 + Erlotinib + Placebo
U3-1287 + Erlotinib + Placebo is a phase 1/2 stage product being developed by Daiichi Sankyo for NSCLC (Advanced Non-small Cell Lung Cancer). The current trial status is completed. This product is registered under clinical trial identifier NCT01211483. Target conditions include NSCLC (Advanced Non-small Cell Lung Cancer).
What happened to similar drugs?
7 of 20 similar drugs in NSCLC (Advanced Non-small Cell Lung Cancer) were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01211483 | Phase 1/2 | Completed |
Competing Products
20 competing products in NSCLC (Advanced Non-small Cell Lung Cancer)